VHL protein‐interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF‐1α
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Hypoxia‐inducible factor (HIF)‐1α is a short‐lived protein and is ubiquitinated and degraded through the von Hippel–Lindau protein (pVHL)–E3 ubiquitin ligase pathway at normoxia. Deubiquitination, by reversing ubiquitination, has been recognized as an important regulatory step in ubiquitination‐related processes. Here, we show that pVHL‐interacting deubiquitinating enzyme 2, VDU2, but not VDU1, interacts with HIF‐1α. VDU2 can specifically deubiquitinate and stabilize HIF‐1α and, therefore, increase expression of HIF‐1α targeted genes, such as vascular endothelial growth factor (VEGF). These findings suggest that ubiquitination of HIF‐1α is a dynamic process and that ubiquitinated HIF‐1α might be rescued from degradation by VDU2 through deubiquitination. Although pVHL functions as a master control for HIF‐1α stabilization, as pVHL–E3 ligase mediates the ubiquitination of both HIF‐1α and VDU2, the balance between the pVHL‐mediated ubiquitination and VDU2‐mediated deubiquitination of HIF‐1α provides another level of control for HIF‐1α stabilization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“HIF-1a is overexpressed in many different human cancers as a result of intratumoral hypoxia as well as genetic alterations (for reviews, see Harris, 2001; Semenza, 2003).”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“In contrast, the O2-dependent prolyl hydroxylation is downregulated under hypoxia, resulting in HIF-1a accumulation and increased HIF-1 activity (Bruick & McKnight, 2001; Epstein et al, 2001; Ivan et al, 2001; Jaakkola et al, 2001).”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Cited by
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
Simsek, T., Kocabas, F., Zheng, J., DeBerardinis, R. J., Mahmoud, A. I., Olson, E. N., Schneider, J. W., Zhang, C. C., & Sadek, H. A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.011 · Cited by 1,101
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032
Hypoxia-Inducible Factor 1 (HIF-1) Pathway
Semenza, G. L. (2007) · Science's STKE · doi:10.1126/stke.4072007cm8 · Cited by 945
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling1
Gereben, B., Zavacki, A. M., Ribich, S., Kim, B. W., Huang, S. A., Simonides, W. S., Zeöld, A., & Bianco, A. C. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0019 · Cited by 891
The role of ubiquitination and deubiquitination in cancer metabolism
Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 508
The ubiquitin-specific protease USP28 is required for MYC stability
Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., Elledge, S. J., & Eilers, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1601 · Cited by 474
Deubiquitinases in cancer: new functions and therapeutic options
Fraile, J. M., Quesada, V, Rodríguez, D., Freije, J. M. P., & López-Otín, C. (2012) · Oncogene · doi:10.1038/onc.2011.443 · Cited by 453
Nagao, A., Kobayashi, M., Koyasu, S., Chow, C. C. T., & Harada, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020238 · Cited by 402
HIF-1 regulation: not so easy come, easy go
Koh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.08.002 · Cited by 339
“The pVHL-interacting de-ubiquitylating enzyme (VDU2; also called USP20) is the sole HIF-1a de-ubiquitylating enzyme (DUB) identified to date [ 31 ].”
BackgroundKaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Percy, M. J., Zhao, Q., Flores, A., Harrison, C., Lappin, T. R. J., Maxwell, P. H., McMullin, M. F., & Lee, F. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508423103 · Cited by 330
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Deubiquitinase inhibition as a cancer therapeutic strategy
D'Arcy, P., Wang, X., & Linder, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 310
Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
Semenza, G. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.69 · Cited by 297
RNA-Binding Proteins HuR and PTB Promote the Translation of Hypoxia-Inducible Factor 1α
Galbán, S., Kuwano, Y., Pullmann, R., Martindale, J. L., Kim, H. H., Lal, A., Abdelmohsen, K., Yang, X., Dang, Y., Liu, J. O., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00973-07 · Cited by 279
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
Hussain, S., Zhang, Y., & Galardy, P. (2009) · Cell Cycle · doi:10.4161/cc.8.11.8739 · Cited by 260
Bracken, C. P., Fedele, A. O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M. L., & Peet, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600288200 · Cited by 222
UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α
Goto, Y., Zeng, L., Yeom, C. J., Zhu, Y., Morinibu, A., Shinomiya, K., Kobayashi, M., Hirota, K., Itasaka, S., Yoshimura, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7153 · Cited by 229
Kietzmann, T., Mennerich, D., & Dimova, E. Y. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00011 · Cited by 176
Targeting ubiquitin specific proteases for drug discovery
Daviet, L., & Colland, F. (2008) · Biochimie · doi:10.1016/j.biochi.2007.09.013 · Cited by 126
Metadata
- Authors
- Li, Z., Wang, D., Messing, E. M., & Wu, G.
- Venue
- EMBO reports
- Published
- 2005-04
- Volume
- 6
- Issue
- 4
- Pages
- 373-378
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2135178058
- Cited by
- 196
- References
- 7
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.